Back to search results

Study of DISC-0974 for Anemia in IBD

This study is testing a drug called DISC-0974 for people who have Inflammatory Bowel Disease (IBD) and also suffer from anemia (low red blood cell count). We want to see if DISC-0974 can safely and effectively improve anemia in these patients. You might be able to join if you are 18 years or older and have a confirmed diagnosis of IBD. The main goal is to see how much DISC-0974 can increase your hemoglobin (a protein in red blood cells) levels over about 85 days. This study is currently recruiting participants.

Study design
This is a Phase 2, randomized, double-blind study involving about 21 participants. Some participants will receive DISC-0974, and others will receive a placebo (an inactive substance).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main measurement for this study is taken through Day 85.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07368972

Study of DISC-0974-201 in Participants With IBD and Anemia

Recruiting
PHASE2Ages 18+InterventionalTreatment
Disc Medicine, Inc
~21 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:DISC-0974Placebo

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximal change from baseline in Hgb through Day 85
Measured over up to 85 days

Conditions

Inflammatory Bowel Disease (IBD)
Anemia
Inflammatory Bowel Disease (IBD); Anemia

Explore related trials

AnemiaInflammatory Bowel DiseaseFerritin

Where it's being run

14 sites across 7 states
Florida6
Ohio2
Texas2
Arizona1
California1
Missouri1
Rhode Island1

Study leadership

  • Will Savage, MD, PhD · STUDY_DIRECTOR · Disc Medicine

Who to contact

Disc Medicine Clinical Trials
[email protected]
(617) 674 9274
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Stable hormonal contraceptive (≥3 months)
Intrauterine device in place for at least 3 months
Tubal ligation or single male partner with vasectomy 12. If a male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
Stable hormonal contraceptive (≥3 months; female partner)
Intrauterine device in place for at least 3 months (female partner)
Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
Confirmed successful vasectomy 13. Able to understand and provide written informed consent. 14. Able to comply with all study procedures.

What this trial measures

  • Maximal change from baseline in Hgb through Day 85up to 85 days